What is the role of PARP inhibitors in the treatment of ovarian cancer?

Updated: Aug 10, 2020
  • Author: Andrew E Green, MD; Chief Editor: Yukio Sonoda, MD  more...
  • Print

Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) enzymes are involved in normal cellular homeostasis (eg, DNA transcription, cell cycle regulation, DNA repair). PARP enzyme inhibitors result in disruption of cellular homeostasis and cell death. The following PARP inhibitors are approved by the US Food and Drug Administration (FDA) for use in ovarian cancer:

  • Olaparib (Lynparza)
  • Rucaparib (Rubraca)
  • Niraparib (Zejula)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!